Epoetin delta
As of the edition of 20 October 2026, Epoetin delta is a protein: withdrawn from the market in 2009; acts on EPOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2009
- Kind
- Protein
- Withdrawn from market
- 17 March 2009 (in some regions)
- Registered trials
- 2, 2 stopped early
- Disease areas
- Blood and lymph; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EPOR | Erythropoietin receptor | P19235 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 2 |